Product Information

SPIRIVA HANDIHALER 18 MCG CAP is a brand product labeled by Boehringer Ingelheim Pharmaceuticals Inc., priced at $11.7350 per EA under NDC 00597007575. Its NADAC has been published 275 times since Feb 19, 2014.

FDA first approved this application on Jan 30, 2004. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

SPIRIVA HANDIHALER 18 MCG CAP

TIOTROPIUM BROMIDE
$11.7350per EA

Strength

18 ug/1

NDC

00597007575

Classification

Brand

Dosage Form

CAPSULE

Route

ORAL; RESPIRATORY (INHALATION)

Effective Date

8/19/2026

Approval Type

New Drug (NDA)

FDA Application

NDA021395

FDA Approved

1/30/2004

TE Code

AB

On Market Since

10/11/2005

Pharmacological Classes

Anticholinergic
Cholinergic Antagonists

Price Statistics

The NADAC for SPIRIVA HANDIHALER 18 MCG CAP has been published 275 times since Feb 19, 2014, and over the history we have for it it has declined 23.1%. The table below summarizes its recorded NADAC range and movement.

Current price$11.7350 per EA
All-time high$19.3463 (Jan 1, 2025)
All-time low$11.5764 (Jun 18, 2025)
52-week high$11.7350
52-week low$11.5764
Median price$13.0192
Average price$14.0742
Largest weekly change+48.0% (Apr 17, 2024)
Weeks tracked275
Tracking sinceFeb 19, 2014

Price History

1W

+0.4%

1M

+0.4%

3M

+0.6%

6M

+0.7%

1Y

+1.4%

3Y

-9.9%

5Y

-9.9%

All

-23.1%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 10% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of SPIRIVA HANDIHALER 18 MCG CAP?

The current National Average Drug Acquisition Cost (NADAC) for SPIRIVA HANDIHALER 18 MCG CAP, manufactured by Boehringer Ingelheim Pharmaceuticals Inc., is $11.7350 per EA (NDC 00597007575), effective Aug 19, 2026.

How has the price of SPIRIVA HANDIHALER 18 MCG CAP changed over time?

Over the history we have for it, the NADAC for SPIRIVA HANDIHALER 18 MCG CAP has declined 23.1%. It has been tracked across 275 weekly CMS publications since Feb 19, 2014.

What are the highest and lowest recorded NADAC prices for SPIRIVA HANDIHALER 18 MCG CAP?

Since Feb 19, 2014, the NADAC for SPIRIVA HANDIHALER 18 MCG CAP has ranged from a low of $11.5764 (Jun 18, 2025) to a high of $19.3463 (Jan 1, 2025), with a median of $13.0192 per EA.

Are there cheaper alternatives to SPIRIVA HANDIHALER 18 MCG CAP?

Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, SPIRIVA HANDIHALER 18 MCG CAP, is $10.6158 per EA — about 10% below SPIRIVA HANDIHALER 18 MCG CAP.

Who manufactures SPIRIVA HANDIHALER 18 MCG CAP?

SPIRIVA HANDIHALER 18 MCG CAP (NDC 00597007575) is labeled by Boehringer Ingelheim Pharmaceuticals Inc., and CMS classifies it as a brand product.